Omega 3 Supplementation in Cystic Fibrosis Patients

NCT00959010 | Completed Phase 3

• 2 other identifiers: HU01/PNE/MUCO12006-004155-38
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Essential fatty acids (EFA) deficiency has been often reported in patients with cystic fibrosis (CF), particularly in those homozygous for the DF508 mutation. Clinical symptoms of CF may be influenced by correcting EFA deficiency. Nevertheless, the value of EFA supplementation in CF remains controversial. Within this multicentric and international randomized placebo-controlled trial it will be evaluated, according to recommendations of Cochrane analysis, beneficial effects of an oral supplementation with polyunsaturated fatty acids on selected biochemical and functional outcome parameters such as inflammatory biomarkers, incorporation into cell membrane phospholipids, lung function, exercise tolerance, clinical and nutritional status and properties of transepithelial ion transport. The study will be undertaken in a cohort of CF patients aged over 6 years old (60 patients), homozygous for the DF508 mutation and treated by Azithromycine. Supplementation will be performed with a triglyceride source at a daily dose of 60 mg/kg of omega-3 polyunsaturated fatty acids (Omega 3 Premiumâ, Laboratoires Ponroy, France). Before enrolled into the trial and during the study, patients will undergo nutritional assessment by evaluation of total and fat dietary intake and overall calorie intake using a 3-days diet records and a food frequency questionnaire. Plasma and erythrocyte membrane EFA profiles and inflammatory markers will be monitored in baseline conditions, at 3, at 6 and 12 months after starting the treatment. Lung function will be performed at each patient visit and an exercise test will be done before and at the end of the treatment. Properties of ion transport will be searched by sweat testing before and at the end of the treatment.

Conditions

Cystic Fibrosis

Keywords

Omega 3; Cystic Fibrosis; Inflammatory markers

Outcome Measures

Primary Outcomes (1)

• LTB4/LTB5 ratio from baseline to the end of treatment assessment.

  Assessment at 3-6-12 months

Secondary Outcomes (6)

• To explore the change in other inflammatory biomarkers such as TNF-alpha, IL-6, IL-8, IL-17 & alpha-1 anti-trypsin.

  Assessments at 3-6 and 12 months

• To evaluate the incorporation into cell membrane phospholipids.

  Assessments at 3-6-12 months

• To evaluate the effects on the pulmonary function (FEV1) and on the exercise tolerance (VO2 max).

  Assessment at 12 months

• To evaluate the effects on the clinical status and the nutritional status.

  Assessments at 3-6-9 and 12 months

• To investigate the properties of transepithelial ion transport (sweat test).

  Assessments at 12 months

Study Arms (2)

Omega 3 Premium

EXPERIMENTAL

capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA

Dietary Supplement: omega-3 triglycerides

Placebo

PLACEBO COMPARATOR

capsules containing middle chain triglycerides

Dietary Supplement: Placebo

Interventions

omega-3 triglycerides DIETARY_SUPPLEMENT

capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.

Omega 3 Premium

Placebo DIETARY_SUPPLEMENT

capsules containing middle chain triglycerides

Placebo

Eligibility Criteria

• Age: 6 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Male or female patient over 6 years of age at visit 1 with stable cystic fibrosis
• Documented Homozygous for DeltaF508 mutation
• Patient treated with stable dose of Azithromycine since at least 3 months
• Able to perform pulmonary function test and swallow capsules
• Female patient of childbearing potential must have a negative serum pregnancy test prior to enrolment and must agree to practice effective birth control during the study and 6 weeks thereafter
• Signed informed consent obtained from the patient, or in case the patient is minor,from patient's legally acceptable representative (parents or guardians) according to ICH \& local regulations. Child assent will be nevertheless obtained

You may not qualify if:

• Ongoing acute illness including acute upper or lower respiratory infections within 2 weeks before baseline evaluation.
• Abnormalities on screening chest x-ray (or CT-scan) suggesting clinically active pulmonary disease other than CF, or new, significant abnormalities such as atelectasis or pleural effusion which may be indicative of clinically active pulmonary involvement secondary to CF.
• Any chronic (\> 1 week daily) oral or intravenous inflammatory treatment, other than Azithromycine, given to the patient within 3 months before start of study treatment.
• Active bleeding or increased risk of bleeding (rate of platelets \< 50,000/mm3,patient treatment by anticoagulant or antiplatelet agents, disturbances of haemostasis with PTT \<70%, bleeding disorders).
• Patient has significant liver disease, defined as having elevated liver function tests with values 2-fold higher than the upper normal range of the investigational local lab or having abnormal ultrasound such as signs of cirrhosis.
• Hypercholesterolemia (\>240mg%).
• Patient is pregnant or a breast-feeding mother
• Patient is participating or has participated in another investigational drug trial or is receiving or has received an investigational drug within the last 28 days before entry into this study.
• Patient is unlikely to comply with the visits scheduled in the protocol or enable to follow the study procedure.

Sponsors & Collaborators

• Queen Fabiola Children's University Hospital: lead

Study Sites (1)

Hôpital Universitaire Des Enfants Reine Fabiola

Brussels, 1020, Belgium

Location

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Officials

• Laurence Hanssens, MD

  Queen Fabiola Children's University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 13, 2009
• First Posted: August 14, 2009
• Study Start: October 1, 2008
• Primary Completion: June 1, 2011
• Last Updated: October 21, 2015

Record last verified: 2015-10

Locations

BE (1)